163 results on '"Panera, Nadia"'
Search Results
2. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease
3. Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
4. Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease
5. Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD
6. Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection
7. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
8. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19
9. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease
10. High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes
11. Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cells via MicroRNA Targeting Peroxisome Proliferator-Activated Receptor-γ
12. FRI-544 KLB depletion fosters stem-like properties and epithelialmesenchymal transition plasticity in HepG2 cells.
13. Perturbation of specific transcripts in peripheral blood mononuclear cells in breast cancer: a case control pilot study
14. The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity.
15. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease
16. Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis.
17. Targeting FGF19 binding to its receptor system: A novel therapeutic approach for hepatocellular carcinoma
18. Association between type two diabetes and non-alcoholic fatty liver disease in youth
19. Blood cell gene expression profiles: A narrative review of biomarkers and effects of low-dose ionizing radiation exposure
20. Hydroxytyrosol Recovers SARS-CoV-2-PLpro-Dependent Impairment of Interferon Related Genes in Polarized Human Airway, Intestinal and Liver Epithelial Cells.
21. Hepatocyte-derived extracellular vesicles released during lipotoxicity regulate hepatic stellate cell pheno-type via delivery of specific miRNAs and modulation of PPAR-γ expression: 25
22. WED-507 - b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype
23. Commentary: FGF21 Holds Promises for Treating Obesity-related Insulin Resistance and Hepatosteatosis
24. Retinoids Counteract Insulin Resistance And Liver Steatosis: Whatʼs the Potential Mechanism?
25. Circulating miRNA profiling to identify biomarkers of dysmetabolism
26. Hepatic stellate cell proliferation: A potential role of protein kinase R
27. Activation of the Endotoxin/Toll-Like Receptor 4 Pathway: The Way to Go From Nonalcoholic Steatohepatitis up to Hepatocellular CarcinomaΔ
28. Toll-Like Receptor 4: A Starting Point for Proinflammatory Signals in Fatty Liver Disease
29. Pediatric Non-Alcoholic Fatty Liver Disease Is Affected by Genetic Variants Involved in Lifespan/Healthspan.
30. TYPE 4 PHOSPHODIESTERASES: A POSSIBLE ROLE IN HEPATOCYTE TRANSFORMATION
31. HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation.
32. Noninvasive diagnostic tools for pediatric NAFLD: where are we now?
33. The pharmacological treatment of nonalcoholic fatty liver disease in children.
34. Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD.
35. Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?
36. From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance.
37. Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD.
38. Intrauterine Growth Retardation and Nonalcoholic Fatty Liver Disease in Children
39. Increase of Intracellular Cyclic AMP by PDE4 Inhibitors Affects HepG2 Cell Cycle Progression and Survival.
40. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma.
41. The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications.
42. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.
43. Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation.
44. Plasma Levels of Homocysteine and Cysteine Increased in Pediatric NAFLD and Strongly Correlated with Severity of Liver Damage.
45. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease.
46. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic Fatty liver disease.
47. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
48. Dual Role of MicroRNAs in NAFLD.
49. Levels of serum ceruloplasmin associate with pediatric nonalcoholic Fatty liver disease.
50. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.